STOCK TITAN

Procaps Group – Notice to Shareholders

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary
Procaps Group, S.A. issued a press release addressing incorrect online voting instructions for the upcoming General Meeting of Shareholders. The Board of Directors has never recommended any vote in favor of the proposals to be voted on. The company is investigating the reason for the inaccurate statement and has requested a correction of all inaccurate statements.
Positive
  • None.
Negative
  • None.

MIAMI & BARRANQUILLA, Colombia.--(BUSINESS WIRE)-- Dear Shareholders,

We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January 22, 2024, were incorrect. Notwithstanding the Company’s diligent review of all relevant materials, a third party unilaterally included on the online version an inaccurate statement that the Board of Directors of the Company had recommended a vote in favor of the proposals to be voted on. We are currently investigating the reason for such erroneous inclusion and have requested a correction of all inaccurate statements.

We are discussing next steps with Company’s counsel but wanted all shareholders of the Company to be aware that the Board of Directors HAS NEVER recommended that the shareholders vote “for” any of the items in the agenda.

Sincerely,

Procaps Group, S.A.

This press release includes “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks included under the header “Risk Factors” in Procaps’ annual report on Form 20-F filed with the SEC, as well as Procaps’ other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Investor Contact:

Melissa Angelini

IR Director - Procaps Group

ir@procapsgroup.com

investor.procapsgroup.com

Source: Procaps Group, S.A.

The online voting instructions were incorrect, and a third party unilaterally included an inaccurate statement that the Board of Directors recommended a vote in favor of the proposals to be voted on.

The General Meeting of Shareholders is scheduled for January 22, 2024.

The company is currently investigating the reason for the erroneous inclusion and has requested a correction of all inaccurate statements.

No, the Board of Directors has never recommended that the shareholders vote 'for' any of the items in the agenda.
Procaps Group S.A

NASDAQ:PROC

PROC Rankings

PROC Latest News

PROC Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
LU
Luxembourg City

About PROC

procaps group has experience in the development of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. we have direct presence in 13 countries in latin america and we have more than 5,000 collaborators working under a sustainable model. we develop, manufacture, and market over-the-counter (otc) and prescription drugs, nutritional supplements and high-potential clinical solutions.